| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial
|
Whyte, Michael P
|
|
2019
|
7 |
2 |
p. 93-105
|
artikel
|
| 2 |
Asfotase alfa treatment in perinatal and infantile hypophosphatasia: safe and sustained efficacy
|
Padidela, Raja
|
|
2019
|
7 |
2 |
p. 76-78
|
artikel
|
| 3 |
Blood glucose meters and test strips: global market and challenges to access in low-resource settings
|
Klatman, Emma Louise
|
|
2019
|
7 |
2 |
p. 150-160
|
artikel
|
| 4 |
Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies
|
Coresh, Josef
|
|
2019
|
7 |
2 |
p. 115-127
|
artikel
|
| 5 |
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials
|
Heerspink, Hiddo J L
|
|
2019
|
7 |
2 |
p. 128-139
|
artikel
|
| 6 |
Correction to Lancet Diabetes Endocrinol 2019; 7: 150–60
|
|
|
2019
|
7 |
2 |
p. e2
|
artikel
|
| 7 |
Correction to Lancet Diabetes Endocrinol 2019; 7: 93–105
|
|
|
2019
|
7 |
2 |
p. e2
|
artikel
|
| 8 |
Food companies and nutrition: beyond mere disclosure
|
Stirrups, Robert
|
|
2019
|
7 |
2 |
p. 92
|
artikel
|
| 9 |
GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects?
|
Zweck, Elric
|
|
2019
|
7 |
2 |
p. 89-90
|
artikel
|
| 10 |
GLP-1 receptor agonists and cardiovascular risk in routine clinical practice
|
Schernthaner, Guntram
|
|
2019
|
7 |
2 |
p. 78-80
|
artikel
|
| 11 |
Incidence and progression of diabetic retinopathy: a systematic review
|
Sabanayagam, Charumathi
|
|
2019
|
7 |
2 |
p. 140-149
|
artikel
|
| 12 |
Research digest: vitamin D supplementation
|
Preiss, David
|
|
2019
|
7 |
2 |
p. 91
|
artikel
|
| 13 |
Spotlight on rare diseases
|
The Lancet Diabetes & Endocrinology,
|
|
2019
|
7 |
2 |
p. 75
|
artikel
|
| 14 |
Subspecialty training in adult inherited metabolic diseases: a call to action for unmet needs
|
Hannah-Shmouni, Fady
|
|
2019
|
7 |
2 |
p. 82-84
|
artikel
|
| 15 |
Use of liraglutide and risk of major cardiovascular events: a register-based cohort study in Denmark and Sweden
|
Svanström, Henrik
|
|
2019
|
7 |
2 |
p. 106-114
|
artikel
|
| 16 |
Vitamin D supplementation and musculoskeletal health
|
Bischoff-Ferrari, Heike A
|
|
2019
|
7 |
2 |
p. 85
|
artikel
|
| 17 |
Vitamin D supplementation and musculoskeletal health
|
Bouillon, Roger
|
|
2019
|
7 |
2 |
p. 85-86
|
artikel
|
| 18 |
Vitamin D supplementation and musculoskeletal health
|
Grant, William B
|
|
2019
|
7 |
2 |
p. 87-88
|
artikel
|
| 19 |
Vitamin D supplementation and musculoskeletal health
|
Martineau, Adrian R
|
|
2019
|
7 |
2 |
p. 86-87
|
artikel
|
| 20 |
Vitamin D supplementation and musculoskeletal health – Authors' reply
|
Bolland, Mark J
|
|
2019
|
7 |
2 |
p. 88-89
|
artikel
|
| 21 |
Working towards novel albuminuria endpoints in chronic kidney disease
|
Fernandez-Fernandez, Beatriz
|
|
2019
|
7 |
2 |
p. 80-82
|
artikel
|
Tijdschrift beschrijving